BIOMAT Database Logo BIOMAT Database Logo

A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503. 2010

Anne M Traynor, and Ju-Whei Lee, and Gerald K Bayer, and John M Tate, and Sachdev P Thomas, and Miroslaw Mazurczak, and David L Graham, and Jill M Kolesar, and Joan H Schiller
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, K6/568 CSC, #5669, 600 Highland Avenue, Madison, WI, 53792, USA. amt@medicine.wisc.edu

BACKGROUND The objective of ECOG 1503 was to determine the response rate of this combination in the second-line treatment of advanced NSCLC. METHODS Triapine 105 mg/m(2) IV on days 1, 8, and 15, and gemcitabine 1,000 mg/m(2) on days 1, 8, and 15, of a 28 day cycle. RESULTS Eighteen patients enrolled. Three patients were not eligible due to protocol violations. No objective antitumor responses were seen. Three patients (20%) experienced stable disease (90% CI 5.7-44%). Median overall survival: 5.4 months (95% CI 4.2-11.6 months); median time to progression: 1.8 months (95% CI 1.7-3.5 months). Five patients developed acute infusion reactions to Triapine related to elevated methemoglobinemia. Patients with MDR1 variant genotypes of C3435T experienced superior overall survival compared to non-variants (13.3 vs. 4.3 months, respectively, p = 0.023). CONCLUSIONS This regimen did not demonstrate activity in relapsed NSCLC. Prolonged survival seen with MDR1 variant genotypes is hypothesis-generating.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008495 Medical Oncology A subspecialty of internal medicine concerned with the study of neoplasms. Oncology, Medical,Clinical Oncology,Oncology, Clinical
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D003299 Cooperative Behavior The interaction of two or more persons or organizations directed toward a common goal which is mutually beneficial. An act or instance of working or acting together for a common purpose or benefit, i.e., joint action. (From Random House Dictionary Unabridged, 2d ed) Compliant Behavior,Behavior, Compliant,Behavior, Cooperative,Compliant Behaviors,Cooperative Behaviors
D003841 Deoxycytidine A nucleoside component of DNA composed of CYTOSINE and DEOXYRIBOSE. Cytosine Deoxyribonucleoside,Cytosine Deoxyriboside,Deoxyribonucleoside, Cytosine,Deoxyriboside, Cytosine
D005260 Female Females

Related Publications

Anne M Traynor, and Ju-Whei Lee, and Gerald K Bayer, and John M Tate, and Sachdev P Thomas, and Miroslaw Mazurczak, and David L Graham, and Jill M Kolesar, and Joan H Schiller
Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial.
July 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Anne M Traynor, and Ju-Whei Lee, and Gerald K Bayer, and John M Tate, and Sachdev P Thomas, and Miroslaw Mazurczak, and David L Graham, and Jill M Kolesar, and Joan H Schiller
Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer: a phase II trial.
August 1998, Seminars in oncology,
Anne M Traynor, and Ju-Whei Lee, and Gerald K Bayer, and John M Tate, and Sachdev P Thomas, and Miroslaw Mazurczak, and David L Graham, and Jill M Kolesar, and Joan H Schiller
Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597.
April 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Anne M Traynor, and Ju-Whei Lee, and Gerald K Bayer, and John M Tate, and Sachdev P Thomas, and Miroslaw Mazurczak, and David L Graham, and Jill M Kolesar, and Joan H Schiller
A phase II study of single-agent gemcitabine as a second-line treatment in advanced non-small cell lung cancer.
January 2006, Japanese journal of clinical oncology,
Anne M Traynor, and Ju-Whei Lee, and Gerald K Bayer, and John M Tate, and Sachdev P Thomas, and Miroslaw Mazurczak, and David L Graham, and Jill M Kolesar, and Joan H Schiller
Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
January 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
Anne M Traynor, and Ju-Whei Lee, and Gerald K Bayer, and John M Tate, and Sachdev P Thomas, and Miroslaw Mazurczak, and David L Graham, and Jill M Kolesar, and Joan H Schiller
Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC): a phase II trial.
January 1999, Anticancer research,
Anne M Traynor, and Ju-Whei Lee, and Gerald K Bayer, and John M Tate, and Sachdev P Thomas, and Miroslaw Mazurczak, and David L Graham, and Jill M Kolesar, and Joan H Schiller
A phase II trial of carboplatin and gemcitabine with exisulind (IND #65,056) in patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (E1501).
September 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
Anne M Traynor, and Ju-Whei Lee, and Gerald K Bayer, and John M Tate, and Sachdev P Thomas, and Miroslaw Mazurczak, and David L Graham, and Jill M Kolesar, and Joan H Schiller
Phase II study of ACNU as second-line treatment in small-cell lung cancer. EORTC Lung Cancer Cooperative Group.
January 1992, Cancer chemotherapy and pharmacology,
Anne M Traynor, and Ju-Whei Lee, and Gerald K Bayer, and John M Tate, and Sachdev P Thomas, and Miroslaw Mazurczak, and David L Graham, and Jill M Kolesar, and Joan H Schiller
Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586).
August 2000, American journal of clinical oncology,
Anne M Traynor, and Ju-Whei Lee, and Gerald K Bayer, and John M Tate, and Sachdev P Thomas, and Miroslaw Mazurczak, and David L Graham, and Jill M Kolesar, and Joan H Schiller
[A phase I study of gemcitabine and irinotecan as second line treatment for advanced non-small cell lung cancer].
February 2003, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!